Neurocrine (NBIX) | Stock Overview & Key Data
Neurocrine Performance Comparison
Stock Range
Today's Range
Low: $131.20
High: $133.25
on August 15, 2025
52 Week Range
Low: $84.23
High: $154.87
on April 9, 2025
on August 23, 2024
All-Time High: $157.98 on July 29, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$13.1B
EPS
3.38
P/E Ratio (TTM)
38.94
Forward P/E
21.19
P/B Ratio
4.84
PEG Ratio
21.19
Div. Yield
N/A
ROE
13.39%
Beta
0.254
Debt to Equity
18.18
Financial Highlights
Profitability
Gross Margin
98.36%
Operating Margin
21.18%
Profit Margin
13.88%
Returns and Earnings
Return on Assets (TTM)
8.67%
Return on Equity (TTM)
13.39%
EBITDA
$493.6M
Net Income (TTM)
$348.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$25.25
Quarterly Revenue Growth (YoY)
16.50%
Quarterly Earnings Growth (YoY)
65.40%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Neurocrine NBIX | 13.05B Large-cap | 6.31% | 1.26% | 10.50% | 16.61% | -3.60% | -8.35% | 24.21% | 17.50% |
| Zoetis ZTS | 65.30B Large-cap | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% | -16.11% | -9.09% | -2.69% |
| Haleon Plc - ADR HLN | 43.62B Large-cap | 1.15% | -0.82% | -9.56% | -3.40% | 2.22% | -0.31% | 61.37% | 30.23% |
| Intra-Cellular ITCI | 14.05B Large-cap | 0.14% | 0.45% | 56.54% | 81.59% | 56.54% | 92.68% | 104.13% | 700.67% |
| United Therapeutics UTHR | 13.63B Large-cap | 3.86% | 6.78% | 3.03% | -16.01% | -13.07% | -2.45% | 39.52% | 191.96% |
| Viatris VTRS | 12.46B Large-cap | 9.38% | 18.81% | 20.71% | -2.30% | -14.57% | -9.01% | 0.38% | -33.65% |
Ownership & Short Interest
Insider Ownership
1.06%
Institutional Ownership
97.91%
Shares Short
3M
Short Ratio
3.10
Short % of Shares Outstanding
3.84%
Average 10-Day Volume
1M
Average 90-Day Volume
983K
Neurocrine Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Neurocrine would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NBIX's 52-week high and low?
- In the last 52 weeks, Neurocrine reached a high of $154.87 (on August 23, 2024) and a low of $84.23 (on April 9, 2025).
- What is the market cap and P/E ratio for NBIX?
- Curious about Neurocrine's size and valuation? Its market capitalization stands at 13.05B. When it comes to valuation, the P/E ratio (trailing twelve months) is 38.94, and the forward P/E (looking ahead) is 21.19.
- Does NBIX pay dividends? If so, what's the yield?
- As for dividends, Neurocrine isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Neurocrine's main competitors or similar companies to consider before investing?
When looking at Neurocrine, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.30B Healthcare Drug Manufacturers - Specialty & Generic -16.11% -9.09% Haleon Plc - ADR
HLN43.62B Healthcare Drug Manufacturers - Specialty & Generic -0.31% 61.37% Intra-Cellular
ITCI14.05B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 104.13% United Therapeutics
UTHR13.63B Healthcare Drug Manufacturers - Specialty & Generic -2.45% 39.52% Viatris
VTRS12.46B Healthcare Drug Manufacturers - Specialty & Generic -9.01% 0.38% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Neurocrine Biosciences Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Neurocrine's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.39%, the Debt to Equity ratio from the most recent quarter is 18.18, and its Gross Profit Margin stands at 98.36%.
- What is the recent revenue and earnings growth for NBIX?
- Looking at Neurocrine's growth, its revenue over the trailing twelve months (TTM) was $3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 16.50%, and quarterly earnings saw a YoY growth of 65.40%.
- How much of NBIX stock is held by insiders and institutions?
- Wondering who owns Neurocrine stock? Company insiders (like executives and directors) hold about 1.06% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 97.91%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.